Drexel University’s online Certificate in Regulatory Affairs for Cell and Gene Therapy trains leaders for this growing discipline and prepares you to bring new therapeutics to market. You'll learn how to manage everything from pre-clinical IND-enabling studies to product licensure, and into post-approval life cycle management, post-approval change reporting categories, accelerated approval mechanisms, managing agency inspections, ethics, CMC, and international market requirements for cell and gene regulatory affairs.
Regulatory affairs for cell and gene therapy (CGT) differs from regulatory affairs for pharmaceutical companies in several key aspects. While both areas involve navigating regulatory requirements and obtaining approvals, CGT presents unique challenges due to the innovative nature of these therapies. Here are some key differences:
Product Complexity
Cell and gene therapies involve complex, personalized products that often require manipulation of a patient's own cells or genetic material. This complexity differs significantly from traditional pharmaceutical products, which are typically small molecules or biologics. The manufacturing, quality control, and characterization processes for CGT products are distinct and require specialized expertise.
Development Process
The development pathway for CGT is often more iterative and dynamic compared to traditional pharmaceuticals. CGT products may undergo multiple modifications during the development process to optimize efficacy and safety. Regulatory affairs professionals working in CGT need to navigate this evolving landscape, including addressing changes in the manufacturing process and adjusting regulatory strategies accordingly.
Clinical Trial Design
Clinical trials for CGT products often involve smaller patient populations due to their personalized nature. Additionally, CGT trials may have unique endpoints and study designs tailored to assess the therapeutic efficacy of these treatments. Regulatory affairs professionals in CGT must have a deep understanding of the specific requirements for designing and conducting trials for these innovative therapies.
Regulatory Framework
Regulatory authorities worldwide have recognized the need for tailored regulations to accommodate the unique aspects of CGT products. Many countries have established specific regulatory frameworks or expedited pathways to facilitate the development and approval of these therapies. Regulatory affairs professionals in CGT need to stay abreast of these evolving regulations and work closely with regulatory agencies to ensure compliance.
Safety and Risk Management
Due to the novel nature of CGT products, safety considerations and risk management play a crucial role in regulatory affairs. Assessing and mitigating potential risks associated with the use of genetically modified cells or vectors is a primary concern. Robust pharmacovigilance programs are necessary to monitor the long-term safety and efficacy of these therapies.
What will I learn in Drexel University’s online PBC in Regulatory Affairs for Cell and Gene Therapy?
Upon completion of the online Certificate in Regulatory Affairs for Cell and Gene Therapy, you will:
Will I have to come to campus during the program?
No, you will not be required to come to campus during this program. However, we do love to see you so please stop by to say hi if you decide to visit Drexel’s campus.
State restrictions may apply to some programs.
|
Required Courses |
||
|
MIIM 573S |
Regulatory Affairs for Cell and Gene Therapy I |
3.0 |
|
MIIM 574S |
Regulatory Affairs for Cell and Gene Therapy II |
3.0 |
|
MIIM 503S |
Biomedical Ethics |
2.0 |
|
Electives (choose 2) |
6.0 |
|
|
CR 514S |
World Wide Regulatory Submissions |
|
|
CR 523S |
Current Issues in Review Boards |
|
|
CR 551S |
International Regulatory Affairs |
|
|
CR 515S |
Intro to Clinical Trials |
|
|
Total Credits |
14.0 |
|
With multiple ways to submit documents, Drexel makes it easy to complete your application. Learn more by visiting our Completing Your Application Guide.
Official test scores from graduate and professional admission exams, such as the Graduate Record Examination (GRE), Graduate Management Admission Test (GMAT), Law School Admission Test (LSAT), or Medical College Admission Test (MCAT), are optional but highly desirable.
For the academic year 2025-2026, students enrolled in an online graduate academic program will be charged a graduate online program fee of $125 per year.
2025-2026 Academic Year
Term
Classes Begin
Classes End
Fall 2025
August 18, 2025
December 12, 2025
Spring 2026
January 5, 2026
May 1, 2026
Summer 2026
May 11, 2026
August 7, 2026